ARVN Stock Summary and Trading Ideas (Arvinas | NASDAQ:ARVN)

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Arvinas trades on the NASDAQ stock market under the symbol ARVN.

As of April 23, 2024, ARVN stock price declined to $34.04 with 301,949 million shares trading.

ARVN has a beta of 2.45, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.14 to the broad based SPY ETF.

ARVN has a market cap of $2.33 billion. This is considered a Mid Cap stock.

Last quarter Arvinas reported $-43 million in Revenue and -$2.53 earnings per share. This fell short of revenue expectation by $-92 million and missed earnings estimates by -$1.25.

In the last 3 years, ARVN stock traded as high as $108.47 and as low as $13.57.

The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, VB, VXF, IWM, VBK.

ARVN has underperformed the market in the last year with a price return of +19.3% while the SPY ETF gained +24.2%. ARVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.9% and -9.6%, respectively, while the SPY returned +4.9% and -2.6%, respectively.

ARVN support price is $33.77 and resistance is $36.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN stock will trade within this expected range on the day.